Looking for a specific product?

Make a search for products & suppliers, articles & news.

Promising Ebola vaccine

Preliminary results from the Norwegian-led trial underway in Guinea, published in the UK medical journal The Lancet, indicate that the vaccine may provide complete protection against Ebola virus disease.

The vaccine study is a collaboration between the public health authorities in Guinea, the World Health Organization (WHO), Doctors Without Borders/Epicentre and the Norwegian Institute of Public Health. The pilot phase of the trial began in late March 2015 and thus far the study has recruited roughly 4 000 trial participants.

“I believe this could be the first effective Ebola vaccine ever developed,” says John-Arne Røttingen of the Norwegian Institute of Public Health. John-Arne Røttingen, Director of the Division of Infectious Disease Control at the Norwegian Institute of Public Health and head of the study’s steering committee, says, “The initial results give us reason to believe this could be the world’s first effective Ebola vaccine ever developed.”

GLOBVAC programme very pleased

“We are very pleased that the results thus far are so encouraging,” says Programme Coordinator of the GLOBVAC programme Åse-Marit Kristiansen. “An effective Ebola vaccine would save many lives.”

“This is a prime example of the importance of strong initiatives in the field of global health and vaccination research as well as of international cooperation in this field,” she adds.

Vaccinating in a ring

The trial employs a “ring vaccination” design that vaccinates a ring of people around new Ebola cases, typically around and including the village or neighbourhood in which the infected person lives.

A randomly selected half of these rings were given the vaccine immediately, while the other half of the rings received the vaccine 21 days later.

The number of infected cases among those immediately vaccinated was then compared to the number of cases identified in the group with delayed vaccination. This enabled researchers to measure the protective effect of the vaccine, while at the same time ensuring that all participants were offered the vaccine, as required under the trial.

Ring vaccination was employed in the campaign to eradicate smallpox in the 1970s but has never before been used in clinical trials.

“Here we clearly see the importance of strong research initiatives in the field of global health and vaccination research,” says Programme Coordinator of the GLOBVAC programme Åse-Marit Kristiansen. Immediate vaccination may give full protection

“None of the participants who received immediate vaccination have become ill so far,” says Dr Røttingen. This could indicate that the vaccine provides complete protection against Ebola. In the control group, by contrast, where participants received the vaccine 21 days later, there were several Ebola cases.

In light of these promising results, an independent committee in charge of monitoring participant safety and the trial outcomes has concluded that it is unethical to continue delaying vaccination. The committee thus recommends that the trial offer vaccines immediately to all those in contact with Ebola-infected people.

“From a strictly scientific point of view we would want more solid data,” explains Dr Røttingen, “but from a public health perspective as well as for ethical reasons we in the steering committee along with WHO have decided to proceed with immediate vaccination of all rings and to publish the interim results.”

Guinea badly affected

Guinea is one of the West African countries most severely affected by the Ebola epidemic. As of the beginning of July 2015 over 11 000 people have died from the disease in West Africa, some 2 500 of them in Guinea.

The continuation of the trial could help to control the still ongoing outbreak in Guinea, and ring vaccination could be relevant for new cases in Sierra Leone as well.

The trial is being funded by the Norwegian Ministry of Foreign Affairs through allocations via the Research Council, as well as by the Wellcome Trust and the Canadian health authorities. In addition, Doctors Without Borders, WHO and the Norwegian Institute of Public Health have invested considerable resources.

Dr Røttingen says the Ebola vaccine will most likely be licensed and available on the market at the earliest in 2016, once necessary approval procedures have been carried out. Recommendations on use are determined by the WHO Strategic Advisory Group of Experts (SAGE), and implementation is determined by the health authorities in each country. The vaccine will most likely be used in ring vaccination in future Ebola outbreaks.

Read about the trial results published in The Lancet.

(This article is primarily based on the Norwegian Institute of Public Health press release published on 31 July 2015.)

 

Related news

Latest news

Introducing SAL R1a Easy Tank

Innovation up to speed – Introducing SAL R1a Easy Tank.

Speed logs for 100 years

This is the story of the Consilium speed logs, helping you navigate for more than 100 years.

IAEA Mission says Research Reactor Operator in Norway is Committed to Safety

A team of eight reactor experts from the International Atomic Energy Agency (IAEA) has for one week undergone the safety of the JEEP II research reactor at Kjeller. The expert group concludes that IFE strongly emphasizes s...

New Research Center for Environment-friendly Energy

The new FME center is dedicated to development of materials, components and technology for use of batteries and hydrogen in zero emission transport systems. It will be a special focus on the maritime sector.

The Netherlands re-join the Halden Reactor Project

The Netherlands signed the Halden Agreement on December 1st and will formally become the 20th member country in the Halden Reactor Project (HRP) after the formal acceptance from the Halden Board during their Paris meeting ...

First phase of DNV GL led offshore cable and pipeline operations equipment joint industry project completed

The data analysed during phase 1 has identified and recorded various processes...

The end of the paper chase: DNV GL to roll out electronic certificates across entire fleet

Certificates are published on DNV GL’s customer portal immediately after an onboard survey is completed,

New Integrated Solution Set to Redefine DP Reference Systems

DPS i2 and DPS i4 utilise KONGSBERG's unique motion gyro compass (MGCTM) and motion reference unit (MRUTM) technology.

Servogear service hub in Asia

September 2017, Servogear announce the strengthening of our presence in Asia with the establishment of a service hub in Singapore.